Leukemia is an uncontrollable growth of hematopoietic cells due to a mutation in DNA
followed by cellular dysregulation and one or more chromosomal disorder that generally leads to a
clonal abnormality. Theoretical and technical inability in early screening and distinguishing cancer,
tumor tolerance to common treatment methods, repeated relapses of cancer after remission phase, heterogeneous
chromosomal abnormality, and the side effects of current chemotherapies are some of challenges
that we face with leukemia and other malignancies. Induced pluripotent stem cells (iPSC)
opened a promising window to a wide range of diseases, including leukemia. Overcoming the barriers
in leukemia is possible with iPSC technology. Induced hematopoietic stem cell transplantation (and
gene therapy), induced cytotoxic T-lymphocytes and reprogrammed NK cells that strengthen the immune
system, miRNAs, modeling approaches, and supportive cares are some aspects of the novel
treatment based on iPSC technology.
Keywords: Leukemia, iPSC, treatment, reprogrammed NK cells, miRNAs, gene therapy, iHSC, malignancy modeling.
Rights & PermissionsPrintExport